Chewy (CHWY)
NYSEConsumer DiscretionarySpecialty RetailSnapshot 2026-09-15
$21.19-0.75%
Close 2026-09-15 · 1-day change
NYSEConsumer DiscretionarySpecialty RetailSnapshot 2026-09-15
Research Workspace
Put CHWY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Discretionary is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Revenue growth of at least 7.9% annually: Q2 FY26 +7.3% vs 7.9% target.
View ThesisManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 57% in its worst 12-month stretch.
View RiskChewy's growth in the health vertical and AI integration has to keep compounding to justify the price. Revenue grew 7.3% year over year, and the last quarter beat expectations. It trades at 21× P/E versus a peer median of 11×, indicating the market is re-rating it beyond its own range. The primary risk is the revenue growth target of at least 7.9% annually, which was missed at 7.3%. Peer multiples imply a price about 7% above where it trades. The thesis has broken due to the revenue growth pillar weakening.
Trailing returns as of 2026-09-15. CHWY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering CHWY (as of Sep 2026).
Based on 13 Wall Street analysts offering 12-month price targets for CHWY in the last 4 months.
Continue this research
Compare CHWY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CHWY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Other Specialty Retail — fair value, gap to price, and forward P/E.
Compare the value case
Put CHWY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive profitable growth with expanding margins
New growth initiatives align with profitable growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $21.19
The last 12 months of price, then the range of analyst 12-month targets from today’s $21.19.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Downgrade indicates potential macroeconomic challenges ahead.
Threatens: Drive profitable growth with expanding margins
Target downgrade indicates potential growth challenges ahead.
Macro headwinds could impact growth objectives.
Advances: Drive profitable growth with expanding margins
Earnings beat indicates strong customer growth and profitability.
Advances: Expand gross margin
Strong sales growth and raised margin support gross margin expansion.
Advances: Achieve consistent net income growth
Q2 earnings show consistent net income growth.
Earnings match and revenue beat support growth objectives.
